DrugPatentWatch Database Preview
Adamas Pharma Company Profile
What is the competitive landscape for ADAMAS PHARMA, and when can generic versions of ADAMAS PHARMA drugs launch?
There are thirteen US patents protecting ADAMAS PHARMA drugs.
There are eighteen patent family members on ADAMAS PHARMA drugs in seven countries.
Summary for Adamas Pharma
| International Patents: | 18 |
| US Patents: | 13 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Adamas Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adamas Pharma | GOCOVRI | amantadine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 208944-002 | Aug 24, 2017 | RX | Yes | Yes | 9,877,933 | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Adamas Pharma | GOCOVRI | amantadine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 208944-001 | Aug 24, 2017 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | |||||
| Adamas Pharma | GOCOVRI | amantadine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 208944-002 | Aug 24, 2017 | RX | Yes | Yes | 8,796,337 | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Adamas Pharma | GOCOVRI | amantadine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 208944-001 | Aug 24, 2017 | RX | Yes | No | 8,895,618 | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Non-Orange Book US Patents for Adamas Pharma
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,987,333 | Composition and method for treating neurological disease | ➤ Try a Free Trial |
| 9,072,697 | Composition and method for treating neurological disease | ➤ Try a Free Trial |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Adamas Pharma Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3132793 | ➤ Try a Free Trial |
| Canada | 2782556 | ➤ Try a Free Trial |
| Japan | 2015131818 | ➤ Try a Free Trial |
| China | 102883601 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
